EMBARGOED FOR MARCH 21, 2012, ARLINGTON, Va.] – The vast majority of sinus infections are caused by viruses and should not be treated with antibiotics, suggest new guidelines released by the Infectious Diseases Society of America (IDSA).
Nearly one in seven people are diagnosed with a sinus infection each year. Although sinus infections are the fifth leading reason for antibiotic prescriptions, 90 to 98 percent of cases are caused by viruses, which are not affected by antibiotics. Used inappropriately, antibiotics foster the development of drug-resistant superbugs.
"There is no simple test that will easily and quickly determine whether a sinus infection is viral or bacterial, so many physicians prescribe antibiotics 'just in case,'" said Anthony W. Chow, MD, chair of the guidelines panel and professor emeritus of infectious diseases at the University of British Columbia, Vancouver. "However, if the infection turns out to be viral – as most are – the antibiotics won't help and in fact can cause harm by increasing antibiotic resistance, exposing patients to drug side effects unnecessarily and adding cost."
The guidelines – the first developed by IDSA on this topic – provide specific characteristics of the illness to help doctors distinguish between viral and bacterial sinus infections. A sinus infection, called acute rhinosinusitis, is inflammation of the nasal and sinus passages that can cause uncomfortable pressure on either side of the nose and last for weeks. Most sinus infections develop during or after a cold or other upper respiratory infection, but other factors such as allergens and environmental irritants may play a role.
The guidelines recommend treating bacterial sinus infections with amoxicillin-clavulanate versus the current standard of care, amoxicillin. The addition of clavulanate helps to overcome antibiotic resistance by inhibiting an enzyme that breaks down the antibiotic. The guidelines also recommend against using other commonly used antibiotics, including azithromycin, clarithromycin and trimethoprim-sulfamethoxazole, due to increasing drug resistance.
The recommendation to use amoxicillin-clavulanate instead of amoxicillin is a major shift from older guidelines developed by other organizations. Dr. Chow notes that this recommendation was made due to increases in antibiotic resistance as well as the common use of pneumococcal vaccines, which have changed the pattern of bacteria that cause sinus infections.
The IDSA guidelines use the new GRADE system (Grading of Recommendations Assessment, Development and Evaluation), which is designed to more clearly assess the quality of evidence and strength of recommendations. The new IDSA guidelines note that randomized controlled trials referenced in previous guidelines often don't differentiate between bacterial and viral cause of infection, and therefore may not provide the best recommendations.
"These are the first evidence-based rhinosinusitis guidelines using the GRADE system," said Thomas M. File Jr., MD, co-author of the guidelines and chair of the Infectious Disease Section at Northeast Ohio Medical University, Rootstown, Ohio. "Health care providers face difficulties when treating sinus infections, and these guidelines provide the best recommendations available. The guidelines are transparent, clearly stating the level of evidence for each recommendation and pointing out where we need more research."
The IDSA rhinosinusitis guidelines contain a number of other recommendations, including:
To ease symptoms of a sinus infection, Dr. File said he recommends patients take acetaminophen for sinus pain, use saline irrigation and drink plenty of fluids.
The voluntary guidelines are not intended to take the place of a doctor's judgment, but rather support the decision-making process, which must be individualized according to each patient's circumstances.
The 11-member guidelines panel comprises rhinosinusitis experts representing a variety of organizations, including the Centers for Disease Control and Prevention (CDC), the American College of Physicians, and the Society of Academic Medicine. In addition to Drs. Chow and File, the rhinosinusitis guidelines panel includes: Michael S. Benninger, Itzhak Brook, Jan L. Brozek, Ellie J.C. Goldstein, Lauri A. Hicks, George A. Pankey, Mitchel Seleznick, Gregory Volturo, and Ellen R. Wald.
IDSA has published more than 50 treatment guidelines on various conditions and infections, ranging from HIV/AIDS to Clostridium difficile. As with other IDSA guidelines, the rhinosinusitis guidelines will be available in a format designed for iPhones and other mobile devices, and in a pocket-sized quick-reference edition. Note: For a copy of the rhinosinusitis guidelines, to be published in the April 15 issue of Clinical Infectious Diseases, please contact Ashley Mattys at (312) 558-1770 or email@example.com. The guidelines are embargoed until 12:01 a.m. EDT on March 21, 2012.
Founded in 1979, Clinical Infectious Diseases publishes clinical articles twice monthly in a variety of areas of infectious disease, and is one of the most highly regarded journals in this specialty.
The Infectious Diseases Society of America (IDSA) is an organization of physicians, scientists, and other health care professionals dedicated to promoting health through excellence in infectious diseases research, education, patient care, prevention, and public health. The Society, which has nearly 10,000 members, was founded in 1963 and is based in Arlington, Va. For more information, see www.idsociety.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.